Preliminary studies showed high rates of deep response in patients with R/R B-ALL and LBCL but emphasized the need to optimize persistence and expansion, both inferior to those achieved with monospecific anti-CD22 CARs. Here, CD22 is linked to acute lymphoblastic leukemia.